Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 15, 2021

Patient-Reported Outcomes With Atezolizumab Plus Bevacizumab vs Sorafenib for Unresectable HCC

The Lancet Oncology


Additional Info

The Lancet Oncology
Patient-Reported Outcomes With Atezolizumab Plus Bevacizumab Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (IMbrave150): An Open-Label, Randomised, Phase 3 Trial
Lancet Oncol 2021 May 27;[EPub Ahead of Print], PR Galle, RS Finn, S Qin, M Ikeda, AX Zhu, TY Kim, M Kudo, V Breder, P Merle, A Kaseb, D Li, S Mulla, W Verret, DZ Xu, S Hernandez, B Ding, J Liu, C Huang, HY Lim, AL Cheng, M Ducreux

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading